免疫实践咨询委员会关于带状疱疹疫苗使用的建议。
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.
作者信息
Dooling Kathleen L, Guo Angela, Patel Manisha, Lee Grace M, Moore Kelly, Belongia Edward A, Harpaz Rafael
出版信息
MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108. doi: 10.15585/mmwr.mm6703a5.
Abstract
On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01), was approved by the Food and Drug Administration for the prevention of herpes zoster in adults aged ≥50 years. The vaccine consists of 2 doses (0.5 mL each), administered intramuscularly, 2-6 months apart (1). On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) recommended the recombinant zoster vaccine (RZV) for use in immunocompetent adults aged ≥50 years.
摘要
2017年10月20日，重组带状疱疹疫苗（佐剂）（欣安立适，葛兰素史克公司，北卡罗来纳州三角研究园），一种两剂次的亚单位疫苗，含重组糖蛋白E并与新型佐剂（AS01）联合，获美国食品药品监督管理局批准用于预防50岁及以上成人的带状疱疹。该疫苗由两剂次（各0.5毫升）组成，通过肌肉注射给药，间隔2至6个月（1）。2017年10月25日，免疫实践咨询委员会（ACIP）建议在免疫功能正常的50岁及以上成人中使用重组带状疱疹疫苗（RZV）。
相似文献
1
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.免疫实践咨询委员会关于带状疱疹疫苗使用的建议。
MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108. doi: 10.15585/mmwr.mm6703a5.
2
Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.《免疫功能低下的成年（≥19 岁）人群使用重组带状疱疹疫苗：免疫接种实践咨询委员会的建议-美国，2022 年》。
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(3):80-84. doi: 10.15585/mmwr.mm7103a2.
3
Update on recommendations for use of herpes zoster vaccine.带状疱疹疫苗使用建议的更新
MMWR Morb Mortal Wkly Rep. 2014 Aug 22;63(33):729-31.
4
Update on the advisory committee on immunization practices' recommendations for use of herpes zoster vaccine.免疫实践咨询委员会关于带状疱疹疫苗使用建议的最新情况。
J Am Osteopath Assoc. 2011 Oct;111(10 Suppl 6):S31-3.
5
Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.带状疱疹重组疫苗的临床和经济影响逐渐增加：预算影响模型中的真实世界数据。
J Manag Care Spec Pharm. 2020 Dec;26(12):1567-1575. doi: 10.18553/jmcp.2020.20251. Epub 2020 Oct 12.
6
Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV).初级保健医生带状疱疹疫苗活（ZVL）接种经验，以及对新型重组带状疱疹疫苗（RZV）的认知和态度。
Vaccine. 2018 Nov 19;36(48):7408-7414. doi: 10.1016/j.vaccine.2018.09.018. Epub 2018 Oct 26.
7
Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.比较活疫苗和重组带状疱疹疫苗的抗体反应。
J Virol. 2021 May 24;95(12). doi: 10.1128/JVI.00240-21.
8
Which patients should receive the herpes zoster vaccine?哪些患者应该接种带状疱疹疫苗？
JAAPA. 2019 Sep;32(9):18-20. doi: 10.1097/01.JAA.0000578788.69674.2b.
9
Cost-effectiveness of the Recommendations of the Advisory Committee on Immunization Practices for the Recombinant Adjuvanted Zoster Subunit Vaccine.免疫实践咨询委员会关于重组佐剂带状疱疹亚单位疫苗建议的成本效益
JAMA Intern Med. 2018 Sep 1;178(9):1277-1278. doi: 10.1001/jamainternmed.2018.3200.
10
Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.在中国≥50 岁成年人中，含佐剂的重组带状疱疹疫苗预防带状疱疹的疗效、反应原性和安全性：一项随机、安慰剂对照试验。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2351584. doi: 10.1080/21645515.2024.2351584. Epub 2024 Jun 5.
引用本文的文献
1
Molecular ingredients of an immunogen for long-lasting IgG.用于产生持久IgG的免疫原的分子成分。
Front Immunol. 2025 Aug 19;16:1639371. doi: 10.3389/fimmu.2025.1639371. eCollection 2025.
2
Immunogenicity of adjuvanted recombinant zoster vaccine in patients with rheumatoid arthritis treated with upadacitinib: 60-week results from a randomised controlled trial substudy.乌帕替尼治疗的类风湿关节炎患者中佐剂重组带状疱疹疫苗的免疫原性：一项随机对照试验子研究的60周结果
RMD Open. 2025 Aug 12;11(3):e005521. doi: 10.1136/rmdopen-2025-005521.
3
Effectiveness and safety of the recombinant zoster vaccine in adult patients with systemic lupus erythematosus: a claims-based retrospective cohort study in the USA.重组带状疱疹疫苗在美国成年系统性红斑狼疮患者中的有效性和安全性：一项基于索赔数据的回顾性队列研究
RMD Open. 2025 Aug 7;11(3):e005839. doi: 10.1136/rmdopen-2025-005839.
4
Prolonged Neurological and Musculoskeletal Symptoms Following Shingrix Vaccination.接种Shingrix疫苗后出现的长期神经和肌肉骨骼症状。
Reports (MDPI). 2024 Oct 9;7(4):83. doi: 10.3390/reports7040083.
5
Research Progress on Varicella-Zoster Virus Vaccines.水痘带状疱疹病毒疫苗的研究进展
Vaccines (Basel). 2025 Jul 4;13(7):730. doi: 10.3390/vaccines13070730.
6
The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018-2024.2018 - 2024年期间，美国疫苗不良事件报告系统（VAERS）中重组带状疱疹疫苗（Shingrix）与流感疫苗联合接种在老年人中的安全性。
Hum Vaccin Immunother. 2025 Dec;21(1):2525603. doi: 10.1080/21645515.2025.2525603. Epub 2025 Jul 11.
7
2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association.《2025年韩国糖尿病管理临床实践指南：韩国糖尿病协会的建议》
Diabetes Metab J. 2025 Jul;49(4):582-783. doi: 10.4093/dmj.2025.0469. Epub 2025 Jul 1.
8
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications.ZOE-LTFU试验至接种疫苗后11年的最终分析：佐剂重组带状疱疹疫苗预防带状疱疹及相关并发症的疗效
EClinicalMedicine. 2025 May 9;83:103241. doi: 10.1016/j.eclinm.2025.103241. eCollection 2025 May.
9
Vaccination coverage, willingness and determinants of herpes zoster vaccine among individuals aged 50 and above in Ningbo, China: A population-based cross-sectional study.中国宁波50岁及以上人群带状疱疹疫苗接种率、接种意愿及影响因素：一项基于人群的横断面研究
Hum Vaccin Immunother. 2025 Dec;21(1):2524247. doi: 10.1080/21645515.2025.2524247. Epub 2025 Jul 2.
10
Human Alpha Herpesviruses Infections (HSV1, HSV2, and VZV), Alzheimer's Disease, and the Potential Benefits of Targeted Treatment or Vaccination-A Virological Perspective.人类α疱疹病毒感染（单纯疱疹病毒1型、单纯疱疹病毒2型和水痘-带状疱疹病毒）、阿尔茨海默病以及靶向治疗或疫苗接种的潜在益处——病毒学视角
Vaccines (Basel). 2025 May 27;13(6):572. doi: 10.3390/vaccines13060572.
本文引用的文献
1
Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults.在老年人中，佐剂带状疱疹病毒亚单位疫苗的免疫应答可持续长达 9 年。
Hum Vaccin Immunother. 2018 Jun 3;14(6):1370-1377. doi: 10.1080/21645515.2018.1442162. Epub 2018 Mar 21.
2
Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study.带状疱疹疫苗预防带状疱疹的长期效果：一项队列研究。
Am J Epidemiol. 2018 Jan 1;187(1):161-169. doi: 10.1093/aje/kwx245.
3
Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.带状疱疹亚单位佐剂疫苗在老年人中的成本效益。
JAMA Intern Med. 2018 Feb 1;178(2):248-258. doi: 10.1001/jamainternmed.2017.7431.
4
Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.带状疱疹亚单位佐剂疫苗在老年人中相隔 2、6 或 12 个月接种 2 剂的免疫原性、反应原性和安全性：III 期、随机、开放标签、多中心研究结果。
Vaccine. 2018 Jan 2;36(1):148-154. doi: 10.1016/j.vaccine.2017.11.019. Epub 2017 Nov 22.
5
Herpes zoster vaccine live: A 10 year review of post-marketing safety experience.带状疱疹活疫苗：上市后安全性经验的 10 年回顾。
Vaccine. 2017 Dec 19;35(52):7231-7239. doi: 10.1016/j.vaccine.2017.11.013. Epub 2017 Nov 22.
6
Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.50岁及以上成年人中，佐剂重组带状疱疹亚单位疫苗与季节性流感疫苗同时接种的免疫原性和安全性
J Infect Dis. 2017 Dec 12;216(11):1352-1361. doi: 10.1093/infdis/jix481.
7
Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.在先前接种过减毒活带状疱疹疫苗的成年人中，重组带状疱疹亚单位疫苗（含 HZ/su 佐剂）的免疫原性和安全性
J Infect Dis. 2017 Dec 12;216(11):1343-1351. doi: 10.1093/infdis/jix482.
8
Effectiveness and Duration of Protection Provided by the Live-attenuated Herpes Zoster Vaccine in the Medicare Population Ages 65 Years and Older.65 岁及以上的 Medicare 人群中，减毒活带状疱疹疫苗提供的保护效力和持续时间。
Clin Infect Dis. 2017 Mar 15;64(6):785-793. doi: 10.1093/cid/ciw854.
9
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.带状疱疹亚单位疫苗在 70 岁及以上成人中的疗效。
N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800.
10
Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient.一名免疫功能低下患者接种带状疱疹疫苗后发生致命性播散性水痘-带状疱疹病毒感染。
BMJ Case Rep. 2016 May 4;2016:bcr2015212688. doi: 10.1136/bcr-2015-212688.
Zotero 插件